FDA Approves World's First Mosquito-Borne Chikungunya Vaccine
Portfolio Pulse from Vandana Singh
The FDA has approved Valneva SE's (NASDAQ:VALN) single-dose Chikungunya vaccine for individuals aged 18 and above. The company plans to start selling the vaccine, Ixchiq, in the U.S. early next year. This makes Ixchiq the world's first licensed Chikungunya vaccine. Valneva's shares are up 6.04% premarket on the news.
November 10, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Valneva's FDA approval for its Chikungunya vaccine and plans to start selling it in the U.S. next year could positively impact its stock.
The FDA approval of Valneva's Chikungunya vaccine is a significant milestone for the company. This could lead to increased revenues as the company starts selling the vaccine in the U.S. next year. The news has already positively impacted the company's stock, with shares up 6.04% premarket.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100